Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial.

Murphy JE, Wo JY, Ryan DP, Jiang W, Yeap BY, Drapek LC, Blaszkowsky LS, Kwak EL, Allen JN, Clark JW, Faris JE, Zhu AX, Goyal L, Lillemoe KD, DeLaney TF, Fernández-Del Castillo C, Ferrone CR, Hong TS.

JAMA Oncol. 2018 Jul 1;4(7):963-969. doi: 10.1001/jamaoncol.2018.0329.

PMID:
29800971
2.

Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in BRAFV600E Colorectal Cancer.

Hazar-Rethinam M, Kleyman M, Han GC, Liu D, Ahronian LG, Shahzade HA, Chen L, Parikh AR, Allen JN, Clark JW, Kwak EL, Faris JE, Murphy JE, Hong TS, Van Seventer EE, Nadres B, Hong CB, Gurski JM Jr, Jessop NA, Dias-Santagata D, Iafrate AJ, Van Allen EM, Corcoran RB.

Cancer Discov. 2018 Apr;8(4):417-427. doi: 10.1158/2159-8290.CD-17-1227. Epub 2018 Feb 5.

PMID:
29431697
3.

Discovery and Optimization of HKT288, a Cadherin-6-Targeting ADC for the Treatment of Ovarian and Renal Cancers.

Bialucha CU, Collins SD, Li X, Saxena P, Zhang X, Dürr C, Lafont B, Prieur P, Shim Y, Mosher R, Lee D, Ostrom L, Hu T, Bilic S, Rajlic IL, Capka V, Jiang W, Wagner JP, Elliott G, Veloso A, Piel JC, Flaherty MM, Mansfield KG, Meseck EK, Rubic-Schneider T, London AS, Tschantz WR, Kurz M, Nguyen D, Bourret A, Meyer MJ, Faris JE, Janatpour MJ, Chan VW, Yoder NC, Catcott KC, McShea MA, Sun X, Gao H, Williams J, Hofmann F, Engelman JA, Ettenberg SA, Sellers WR, Lees E.

Cancer Discov. 2017 Sep;7(9):1030-1045. doi: 10.1158/2159-8290.CD-16-1414. Epub 2017 May 19.

PMID:
28526733
4.

A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer.

van Geel RMJM, Tabernero J, Elez E, Bendell JC, Spreafico A, Schuler M, Yoshino T, Delord JP, Yamada Y, Lolkema MP, Faris JE, Eskens FALM, Sharma S, Yaeger R, Lenz HJ, Wainberg ZA, Avsar E, Chatterjee A, Jaeger S, Tan E, Maharry K, Demuth T, Schellens JHM.

Cancer Discov. 2017 Jun;7(6):610-619. doi: 10.1158/2159-8290.CD-16-0795. Epub 2017 Mar 31.

5.

Tolerability and Long-term Outcomes of Dose-Painted Neoadjuvant Chemoradiation to Regions of Vessel Involvement in Borderline or Locally Advanced Pancreatic Cancer.

Wo JY, Niemierko A, Ryan DP, Blaszkowsky LS, Clark JW, Kwak EL, Lillemoe KD, Drapek LN, Zhu AX, Allen JN, Faris JE, Murphy JE, Nipp R, Fernandez-Del Castillo C, Ferrone CR, Hong TS.

Am J Clin Oncol. 2018 Jul;41(7):656-661. doi: 10.1097/COC.0000000000000349.

PMID:
28134673
6.

Phase I Study of the Investigational Anti-Guanylyl Cyclase Antibody-Drug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal Malignancies.

Almhanna K, Kalebic T, Cruz C, Faris JE, Ryan DP, Jung J, Wyant T, Fasanmade AA, Messersmith W, Rodon J.

Clin Cancer Res. 2016 Oct 15;22(20):5049-5057. Epub 2016 May 13.

7.

FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis.

Suker M, Beumer BR, Sadot E, Marthey L, Faris JE, Mellon EA, El-Rayes BF, Wang-Gillam A, Lacy J, Hosein PJ, Moorcraft SY, Conroy T, Hohla F, Allen P, Taieb J, Hong TS, Shridhar R, Chau I, van Eijck CH, Koerkamp BG.

Lancet Oncol. 2016 Jun;17(6):801-810. doi: 10.1016/S1470-2045(16)00172-8. Epub 2016 May 6. Review.

8.

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.

Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, Wolf J, Raje NS, Diamond EL, Hollebecque A, Gervais R, Elez-Fernandez ME, Italiano A, Hofheinz RD, Hidalgo M, Chan E, Schuler M, Lasserre SF, Makrutzki M, Sirzen F, Veronese ML, Tabernero J, Baselga J.

N Engl J Med. 2015 Aug 20;373(8):726-36. doi: 10.1056/NEJMoa1502309.

9.

Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma.

Goyal L, Govindan A, Sheth RA, Nardi V, Blaszkowsky LS, Faris JE, Clark JW, Ryan DP, Kwak EL, Allen JN, Murphy JE, Saha SK, Hong TS, Wo JY, Ferrone CR, Tanabe KK, Chong DQ, Deshpande V, Borger DR, Iafrate AJ, Bardeesy N, Zheng H, Zhu AX.

Oncologist. 2015 Sep;20(9):1019-27. doi: 10.1634/theoncologist.2015-0210. Epub 2015 Aug 5.

10.

Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.

Ahronian LG, Sennott EM, Van Allen EM, Wagle N, Kwak EL, Faris JE, Godfrey JT, Nishimura K, Lynch KD, Mermel CH, Lockerman EL, Kalsy A, Gurski JM Jr, Bahl S, Anderka K, Green LM, Lennon NJ, Huynh TG, Mino-Kenudson M, Getz G, Dias-Santagata D, Iafrate AJ, Engelman JA, Garraway LA, Corcoran RB.

Cancer Discov. 2015 Apr;5(4):358-67. doi: 10.1158/2159-8290.CD-14-1518. Epub 2015 Feb 11.

11.

Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.

Ferrone CR, Marchegiani G, Hong TS, Ryan DP, Deshpande V, McDonnell EI, Sabbatino F, Santos DD, Allen JN, Blaszkowsky LS, Clark JW, Faris JE, Goyal L, Kwak EL, Murphy JE, Ting DT, Wo JY, Zhu AX, Warshaw AL, Lillemoe KD, Fernández-del Castillo C.

Ann Surg. 2015 Jan;261(1):12-7. doi: 10.1097/SLA.0000000000000867.

12.

Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer.

Hezel AF, Noel MS, Allen JN, Abrams TA, Yurgelun M, Faris JE, Goyal L, Clark JW, Blaszkowsky LS, Murphy JE, Zheng H, Khorana AA, Connolly GC, Hyrien O, Baran A, Herr M, Ng K, Sheehan S, Harris DJ, Regan E, Borger DR, Iafrate AJ, Fuchs C, Ryan DP, Zhu AX.

Br J Cancer. 2014 Jul 29;111(3):430-6. doi: 10.1038/bjc.2014.343. Epub 2014 Jun 24.

13.

Mutational analysis and clinical correlation of metastatic colorectal cancer.

Russo AL, Borger DR, Szymonifka J, Ryan DP, Wo JY, Blaszkowsky LS, Kwak EL, Allen JN, Wadlow RC, Zhu AX, Murphy JE, Faris JE, Dias-Santagata D, Haigis KM, Ellisen LW, Iafrate AJ, Hong TS.

Cancer. 2014 May 15;120(10):1482-90. doi: 10.1002/cncr.28599. Epub 2014 Feb 5.

14.

Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma.

Borger DR, Goyal L, Yau T, Poon RT, Ancukiewicz M, Deshpande V, Christiani DC, Liebman HM, Yang H, Kim H, Yen K, Faris JE, Iafrate AJ, Kwak EL, Clark JW, Allen JN, Blaszkowsky LS, Murphy JE, Saha SK, Hong TS, Wo JY, Ferrone CR, Tanabe KK, Bardeesy N, Straley KS, Agresta S, Schenkein DP, Ellisen LW, Ryan DP, Zhu AX.

Clin Cancer Res. 2014 Apr 1;20(7):1884-90. doi: 10.1158/1078-0432.CCR-13-2649. Epub 2014 Jan 29.

15.

The controversial role of chemoradiation for patients with locally advanced pancreatic cancer.

Faris JE, Wo JY.

Oncologist. 2013;18(9):981-5. doi: 10.1634/theoncologist.2013-0270. Epub 2013 Sep 10. No abstract available.

16.

Controversy and consensus on the management of patients with pseudomyxoma peritonei.

Faris JE, Ryan DP.

Curr Treat Options Oncol. 2013 Sep;14(3):365-73. doi: 10.1007/s11864-013-0240-x.

PMID:
23934509
17.

FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience.

Faris JE, Blaszkowsky LS, McDermott S, Guimaraes AR, Szymonifka J, Huynh MA, Ferrone CR, Wargo JA, Allen JN, Dias LE, Kwak EL, Lillemoe KD, Thayer SP, Murphy JE, Zhu AX, Sahani DV, Wo JY, Clark JW, Fernandez-del Castillo C, Ryan DP, Hong TS.

Oncologist. 2013;18(5):543-8. doi: 10.1634/theoncologist.2012-0435. Epub 2013 May 8.

18.

Trees, forests, and other implications of a BRAF mutant gene signature in patients with BRAF wild-type disease.

Faris JE, Ryan DP.

J Clin Oncol. 2012 Apr 20;30(12):1255-7. doi: 10.1200/JCO.2011.41.1512. Epub 2012 Mar 5. No abstract available.

PMID:
22393091
19.

Targeted therapy for biliary tract cancers.

Faris JE, Zhu AX.

J Hepatobiliary Pancreat Sci. 2012 Jul;19(4):326-36. doi: 10.1007/s00534-011-0496-0. Review.

PMID:
22318523
20.

A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer.

Faris JE, Arnott J, Zheng H, Ryan DP, Abrams TA, Blaszkowsky LS, Clark JW, Enzinger PC, Hezel AF, Ng K, Wolpin BM, Kwak EL.

Invest New Drugs. 2012 Aug;30(4):1614-20. doi: 10.1007/s10637-011-9708-3. Epub 2011 Jul 29.

21.

Metabolic sequelae associated with androgen deprivation therapy for prostate cancer.

Faris JE, Smith MR.

Curr Opin Endocrinol Diabetes Obes. 2010 Jun;17(3):240-6. doi: 10.1097/MED.0b013e3283391fd1. Review.

22.

Targeted therapies: Sunitinib versus interferon-alpha in metastatic RCC.

Faris JE, Michaelson MD.

Nat Rev Clin Oncol. 2010 Jan;7(1):7-8. doi: 10.1038/nrclinonc.2009.173.

PMID:
20029441
23.

Primary mediastinal large B-cell lymphoma.

Faris JE, LaCasce AS.

Clin Adv Hematol Oncol. 2009 Feb;7(2):125-33.

PMID:
19367254
24.

Sunitinib (sutent)-induced thyrotoxicosis due to destructive thyroiditis: a case report.

Faris JE, Moore AF, Daniels GH.

Thyroid. 2007 Nov;17(11):1147-9.

PMID:
17714037
25.

Time tells the tale.

Faris JE, Brown CD.

Am J Med. 2005 Aug;118(8):840-2. No abstract available. Erratum in: Am J Med. 2007 Apr;120(4):e3.

PMID:
16084175
26.

Plasmid DNA vaccines: assay for integration into host genomic DNA.

Ledwith BJ, Manam S, Troilo PJ, Barnum AB, Pauley CJ, Griffiths TG 2nd, Harper LB, Schock HB, Zhang H, Faris JE, Way PA, Beare CM, Bagdon WJ, Nichols WW.

Dev Biol (Basel). 2000;104:33-43.

PMID:
11713822
27.

Health education spans outreach clinics: a concept to consider.

Hardy WE Jr, Marshall JP, Faris JE.

Health Educ Monogr. 1975 Spring;3(1):89-99. No abstract available.

PMID:
1133009

Supplemental Content

Loading ...
Support Center